{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:14:49Z","timestamp":1793121289752,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"SetPoint Medical"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40744-025-00798-y","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:21:50Z","timestamp":1760088110000},"page":"1125-1136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Neuroimmune Modulation for Drug-Refractory Rheumatoid Arthritis: Long-Term Safety and Efficacy in Patients Enrolled in a Pilot Vagus Nerve Stimulation Study"],"prefix":"10.1007","volume":"12","author":[{"given":"Norman B.","family":"Gaylis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sikes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane Lewis","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaakov A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chernoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"issue":"13","key":"798_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360\u201372.","journal-title":"JAMA"},{"issue":"5","key":"798_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","volume":"36","author":"PC Taylor","year":"2016","unstructured":"Taylor PC, Moore A, Vasilescu R, et al. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36(5):685\u201395.","journal-title":"Rheumatol Int"},{"issue":"9","key":"798_CR3","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00296-017-3726-1","volume":"37","author":"TM Hunter","year":"2017","unstructured":"Hunter TM, Boytsov NN, Zhang X, et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004\u20132014. Rheumatol Int. 2017;37(9):1551\u20137.","journal-title":"Rheumatol Int"},{"issue":"Suppl 2","key":"798_CR4","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1007\/s10198-007-0088-8","volume":"8","author":"J Lundkvist","year":"2008","unstructured":"Lundkvist J, Kast\u00e4ng F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ. 2008;8(Suppl 2):S49-60.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"798_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3109\/14397595.2013.854059","volume":"24","author":"H Yamanaka","year":"2014","unstructured":"Yamanaka H, Sugiyama N, Inoue E, et al. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol. 2014;24(1):33\u201340.","journal-title":"Mod Rheumatol"},{"issue":"7","key":"798_CR6","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108\u201323.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"798_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RB, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"798_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.semarthrit.2013.07.011","volume":"43","author":"I Flouri","year":"2014","unstructured":"Flouri I, Markatseli TE, Voulgari PV, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014;43(4):447\u201357.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"798_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4236\/ojra.2013.32011","volume":"3","author":"J Pope","year":"2013","unstructured":"Pope J, Combe B. Unmet needs in the treatment of rheumatoid arthritis. Open J Rheumatol Autoimmune Dis. 2013;3(2):65\u201378.","journal-title":"Open J Rheumatol Autoimmune Dis"},{"issue":"7","key":"798_CR10","first-page":"1135","volume":"57","author":"MJ de Hair","year":"2018","unstructured":"de Hair MJ, Jacobs JW, Schoneveld JL, et al. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology. 2018;57(7):1135\u201344.","journal-title":"Rheumatology"},{"issue":"9","key":"798_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.autrev.2017.07.012","volume":"16","author":"R Giacomelli","year":"2017","unstructured":"Giacomelli R, Afeltra A, Alunno A, et al. International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome, and Sjogren\u2019s syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017;16(9):911\u201324.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"798_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/rheumatology\/key338","volume":"58","author":"IC Olsen","year":"2019","unstructured":"Olsen IC, Lie E, Vasilescu R, et al. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. Rheumatology. 2019;58(3):481\u201391.","journal-title":"Rheumatology"},{"issue":"186","key":"798_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.clim.2017.08.009","volume":"1","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Strand V, van der Heijde D, et al. The unmet need in rheumatology: reports from the targeted therapies meeting 2017. Clin Immunol. 2018;1(186):87\u201393.","journal-title":"Clin Immunol"},{"issue":"1","key":"798_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NM, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(1):31\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"6917","key":"798_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nature01321","volume":"420","author":"KJ Tracey","year":"2002","unstructured":"Tracey KJ. The inflammatory reflex. Nature. 2002;420(6917):853\u20139.","journal-title":"Nature"},{"issue":"9","key":"798_CR16","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1136\/ard.2009.118554","volume":"69","author":"MA van Maanen","year":"2010","unstructured":"van Maanen MA, Stoof SP, LaRosa GJ, et al. Role of the cholinergic nervous system in rheumatoid arthritis: aggravation of arthritis in nicotinic acetylcholine receptor \u03b17 subunit gene knockout mice. Ann Rheum Dis. 2010;69(9):1717\u201323.","journal-title":"Ann Rheum Dis"},{"key":"798_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1600-065X.2012.01138.x","volume":"248","author":"PS Olofsson","year":"2012","unstructured":"Olofsson PS, Rosas-Ballina M, Levine YA, Tracey KJ. Rethinking inflammation: neural circuits in the regulation of immunity. Immunol Rev. 2012;248:188\u2013204.","journal-title":"Immunol Rev"},{"issue":"8","key":"798_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104530","volume":"9","author":"YA Levine","year":"2014","unstructured":"Levine YA, Koopman FA, Faltys M, et al. Neurostimulation of the cholinergic anti-inflammatory pathway ameliorates disease in rat collagen-induced arthritis. PLoS ONE. 2014;9(8):e104530.\u00a0","journal-title":"PLoS ONE"},{"key":"798_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.bbi.2017.04.003","volume":"64","author":"GS Bassi","year":"2017","unstructured":"Bassi GS, Dias DPM, Franchin M, et al. Modulation of experimental arthritis by vagal sensory and central brain stimulation. Brain Behav Immun. 2017;64:330\u201343.\u00a0","journal-title":"Brain Behav Immun"},{"key":"798_CR20","doi-asserted-by":"crossref","unstructured":"Levine YA, Faltys M, Zitnik R. Activation of the inflammatory reflex in rheumatoid arthritis and inflammatory bowel disease; preclinical evidence. In: Krames R, Peckham, editors. Neuromodulation, 2nd ed. London: Elsevier; 2018. p. 1493\u20131502.","DOI":"10.1016\/B978-0-12-805353-9.00126-1"},{"issue":"7","key":"798_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100696","volume":"3","author":"MJ Kelly","year":"2022","unstructured":"Kelly MJ, Breathnach C, Tracey KJ, et al. Manipulation of the inflammatory reflex as a therapeutic strategy. Cell Rep Med. 2022;3(7):100696.","journal-title":"Cell Rep Med"},{"issue":"29","key":"798_CR22","doi-asserted-by":"publisher","first-page":"8284","DOI":"10.1073\/pnas.1605635113","volume":"113","author":"FA Koopman","year":"2016","unstructured":"Koopman FA, Chavan SS, Miljko S, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci USA. 2016;113(29):8284\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"798_CR23","doi-asserted-by":"publisher","first-page":"e527","DOI":"10.1016\/S2665-9913(20)30172-7","volume":"2","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Gaylis NB, Sikes D, et al. Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. Lancet Rheumatol. 2020;2(9):e527\u201338.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"798_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s42234-023-00138-x","volume":"10","author":"D Peterson","year":"2024","unstructured":"Peterson D, Van Poppel M, Boling W, et al. Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. Bioelectron Med. 2024;10(1):8.","journal-title":"Bioelectron Med"},{"issue":"1","key":"798_CR25","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034330","volume":"10","author":"YA Levine","year":"2020","unstructured":"Levine YA, Faltys M, Chernoff D. Harnessing the inflammatory reflex for the treatment of inflammation-mediated diseases. Cold Spring Harb Perspect Med. 2020;10(1):a034330.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"13","key":"798_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.869205","volume":"12","author":"KB Moosic","year":"2022","unstructured":"Moosic KB, Ananth K, Andrade F, Feith DJ, Darrah E, Loughran JTP. Intersection between large granular lymphocyte leukemia and rheumatoid arthritis. Front Oncol. 2022;12(13):869205.","journal-title":"Front Oncol"},{"key":"798_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar3249","volume":"13","author":"R Rendas-Baum","year":"2011","unstructured":"Rendas-Baum R, Wallenstein GV, Koncz T, et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-\u03b1 inhibitors. Arthritis Res Ther. 2011;13:1\u20135.","journal-title":"Arthritis Res Ther"},{"issue":"16","key":"798_CR28","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1212\/WNL.0b013e3182a393d1","volume":"81","author":"GL Morris III","year":"2013","unstructured":"Morris GL III, Gloss D, Buchhalter J, et al. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(16):1453\u20139.","journal-title":"Neurology"},{"issue":"1","key":"798_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1212\/WNL.51.1.48","volume":"51","author":"A Handforth","year":"1998","unstructured":"Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology. 1998;51(1):48\u201355.","journal-title":"Neurology"},{"issue":"83","key":"798_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.seizure.2020.09.027","volume":"1","author":"DH Toffa","year":"2020","unstructured":"Toffa DH, Touma L, El Meskine T, Bouthillier A, Nguyen DK. Learnings from 30\u00a0years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: a critical review. Seizure. 2020;1(83):104\u201323.","journal-title":"Seizure"},{"issue":"6","key":"798_CR31","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10286-024-01065-w","volume":"34","author":"CW Austelle","year":"2024","unstructured":"Austelle CW, Cox SS, Wills KE, Badran BW. Vagus nerve stimulation (VNS): recent advances and future directions. Clin Auton Res. 2024;34(6):529\u201347.","journal-title":"Clin Auton Res"},{"issue":"1","key":"798_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s42234-023-00138-x","volume":"10","author":"D Person","year":"2024","unstructured":"Person D, Van Poppel M, Boling W, et al. Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. Bioelectron Med. 2024;10(1):8.","journal-title":"Bioelectron Med"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00798-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00798-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00798-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:46:41Z","timestamp":1763732801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00798-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["798"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00798-y","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Norman B Gaylis reports personal fees from Arthritis and Rheumatic Disease Specialties, during the conduct of the study. Alan Kivitz is involved in a clinical research trial sponsored by Altoona Center for Clinical Research, during the conduct of the study; reports personal fees from AbbVie, Celgene, Horizon, Janssen, Merck, Genzyme, Regeneron, Sun Pharma Advanced Research, Boehringer Ingeleheim, and Flexion, personal fees, participation on an advisory committee or review panel, and stock ownership from Pfizer and Sanofi, personal and consultant fees, and stock ownership for Gilead, and stock ownership in Amgen and GlaxoSmithKline, outside of the submitted work. Melissa Evangelista reports personal fees and stock from SetPoint Medical, outside of the submitted work, and is an employee of SetPoint Medical. Yaakov A Levine reports personal fees and stock from SetPoint Medical, outside of the submitted work,\u00a0and is an employee of SetPoint Medical. YAL also holds several patents around use of vagus nerve stimulation for inflammatory disease. David Chernoff reports personal fees, outside of the submitted work, and is an employee and stockholder at SetPoint Medical. David Sikes and Diane Lewis Horowitz declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study complied with the Declaration of Helsinki and Good Clinical Practice Guidelines established by the International Conference on Harmonization. The institutional review board and independent ethics committees at each investigational center (Biomedical Research Alliance of NY and Western Copernicus Group) reviewed and approved the final protocol and informed consent documentation. All patients provided their written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}